###### Strengths and limitations of this study

-   The Lilac study focuses on two main problems of antiretroviral therapy (ART)-treated people living with HIV (PLWH): immune activation and HIV reservoirs.

-   Metformin is a well-tolerated antihyperglycaemic drug with anti-inflammatory effects which has been shown to restore T-cell function.

-   We hypothesise that metformin treatment in PLWH on ART will allow immune activation reduction and a diminution of the HIV reservoir size.

-   We will assess changes induces by metformin in both in blood and colon biopsies.

-   Although the Lilac study is a pilot trial on 22 PLWH on ART, it should provide sufficient sample size calculations for larger studies.

Introduction {#s1}
============

HIV persistence during antiretroviral therapy {#s1a}
---------------------------------------------

Antiretroviral therapy (ART) decreases HIV plasma viral load below the limit of detection of clinical assays, leading to major improvements in the health of people living with HIV (PLWH). However, these individuals on prolonged ART develop signiﬁcant metabolic complications that contribute to an increased risk of inflammatory non-AIDS events.[@R1] Such clinical events are associated with persistent immune activation, and occur more often when ART initiation is delayed.[@R2] ART cannot clear latently infected memory CD4+ T cells, which persist to form the viral reservoir, responsible for the rapid viral rebound upon ART interruption.[@R5] Determinants of the size of the HIV reservoir include late ART initiation, low CD4+ T cell count, low CD4+/CD8+ ratio despite CD4+ T cell recovery and high levels of immune activation.[@R7] Conversely, elite controllers, who have strong polyfunctional HIV-specific cytotoxic T-lymphocytes, have a smaller reservoir compared with ART-treated individuals.[@R11] These observations support a direct relationship between the quality of the HIV-specific immune response, level of inflammation and HIV reservoir size. Therefore, strategies aiming at targeting and reducing immune activation and improving T-cell function may reduce the size of the HIV reservoir.

We and others have demonstrated that during primary HIV infection, the altered metabolic state of HIV-specific CD8+ T cells leads to persistent immune activation and immune exhaustion.[@R13] These findings indicate that metabolism acts upstream of immune activation and influences immune responses.[@R16] During chronic HIV infection, the switch from oxidative phosphorylation to aerobic glycolytic metabolism in response to persistent antigenic stimulation leads to terminal differentiation, reducing the pool of central memory T-cells.[@R17] Such metabolic changes at the cellular level are regulated by nutrient-sensing and activation signalling pathways mainly mediated by phosphoinositide 3-kinase, mammalian target of rapamycin (mTOR) and adenosine monophosphate-activated protein kinase (AMPK).[@R19] As for cancer cells, a 'Warburg effect' occurs whereby glucose transport is markedly increased via aerobic glycolysis following persistent T-cell activation.[@R20] Notably, during chronic viral infections, the energy sensor AMPK modulates glucose uptake for fuelling T-cell cytotoxic function.[@R21]

Collectively, these findings suggest that immunometabolism, which regulates T-cell proliferation and cytotoxic responses, may influence the size of the HIV reservoir.[@R23] Therefore, medication that improves T-cell metabolism may enhance their function and may contribute to immune control of the HIV reservoir.

Metformin is an antidiabetic drug with immunometabolic effects {#s1b}
--------------------------------------------------------------

Isolated in the 1920s from French lilac, metformin (dimethylbiguanide) is widely used as a first-line treatment for type II diabetes.[@R24] This drug, which has limited side effects, acts as an antihyperglycaemic agent that promotes euglycaemia without the risk of hypoglycaemia.[@R25] By improving insulin sensitivity, metformin decreases insulin resistance in non-insulin-dependent diabetics by activating AMPK, thereby reducing hepatic gluconeogenesis and increasing glucose uptake in skeletal muscles.[@R26]

Metformin was recently shown to promote longevity in worms, rodents and diabetic individuals by mimicking a state of induced dietary restriction.[@R27] Metformin has been demonstrated to decrease cancer and myocardial infarction-related mortality in diabetic individuals, in addition to enhancing memory T-cell generation in mice.[@R28] Mechanistically, metformin inhibits mTOR signalling independently of the insulin-signalling pathway by: (1) activating AMPK, a heterotrimeric serine/threonine kinase complex that monitors cellular energy levels and acts as an upstream inhibitor of mTOR and (2) inhibiting Rag GTPases.[@R30]

Metformin promotes autophagy and modulates T-cell glycolysis by inhibiting mTOR, improving CD4+ T cell counts in diabetic PLWH initiating ART.[@R31] The effects of metformin in PLWH may be due to: (1) its ability to overcome the inhibition AMPK by viral transactivator of transcription (Tat) protein[@R32]; (2) an anti-inflammatory effect on the intestine by suppressing nuclear factor κB activation[@R33]; (3) an indirect anti-inflammatory effect caused by the reduced production of cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1)[@R34] and/or (4) changes in the composition of the gut microbiota which have been observed in mice and in humans.[@R35] This last observation occurred in the absence of a glycaemic effect when metformin was administered intravenously to mice,[@R39] suggesting that the microbiota plays a predominant role in metformin effect. The ability of metformin to affect the composition of the gut microbiota may also contribute to metformin's antidiabetic effect given that dysbiosis, that is an imbalance in the composition of the microbiota, has been directly associated with insulin resistance related to lipopolysaccharide (LPS)-induced inflammation.[@R35] Indeed, plasma levels of LPS are elevated in PLWH.[@R40]

Metformin has been recently considered to be an 'oncobiguanide' due to its immunometabolic effect on cancer cells, paving the way for its current investigation in non-diabetic cancer patients.[@R43] Gong *et al* have further shown that the use of metformin by diabetic, postmenopausal women was associated with a reduced risk of breast cancer and reduced risk of death from cancer, compared with the use of other antidiabetic medications including insulin.[@R44]

In non-diabetic women treated for polycystic ovary syndrome, 12 weeks of metformin decreased levels of intracellular adhesion molecule-1, E-selectin, IL-6 and TNF-α.[@R45] Recently, metformin was shown to have limited toxicity compared with placebo in non-diabetic, pregnant, obese women who received a daily prophylactic dose of 3.0 g from 12 to 18 weeks of gestation until delivery.[@R46] Encouragingly, these patients had reduced maternal gestational weight gain and a lower rate of pre-eclampsia compared with patients who received a placebo.

Based on its low toxicity profile[@R46] and its ability to activate AMPK and to inhibit mTOR signalling, metformin is a promising new immunometabolic candidate.[@R19] We hypothesise that in addition to ART, metformin could decrease immune activation and restore CD8+ T cell function to decrease the size of the HIV reservoir. Therefore, we designed a pilot study to test this hypothesis and to obtain estimates for sample size calculations required for larger scale studies.

Objectives {#s1c}
----------

To establish the feasibility and optimal design of a full-scale study on the effect of metformin in ART-treated PLWH, we designed a single-arm pilot study.

### Primary outcomes {#s1c1}

The primary outcome of this study will be the change in the size of the HIV reservoir in blood before and after 12 weeks of metformin, and after 12 weeks of metformin discontinuation as determined by PCR-based assays (total and integrated HIV DNA).

### Secondary outcomes {#s1c2}

The secondary outcomes of this study will be the following:Safety of adding 12 weeks of metformin treatment to suppressive ART in PLWH.Change in the size of the HIV reservoir in colon biopsies before and after 12 weeks of metformin, as determined by PCR-based assays (total and integrated HIV DNA).The change in the size of the HIV reservoir before and after 12 weeks of metformin as determined by tat/rev induced limiting dilution assay (TILDA), a novel PCR-based assay that quantifies the frequency of CD4+ T-cells harbouring inducible HIV.[@R47]The change in immune activation before and after 12 weeks of metformin as measured by changes in the percentage of human leukocyte antigen-DR isotype (HLA-DR) and CD38 expressing T-cells, in both blood and colon biopsies.

### Exploratory outcomes {#s1c3}

The exploratory outcomes of this study will be the changes in the following before and after 12 weeks of metformin use, and after 12 weeks of metformin discontinuation.The absolute CD4+ and CD8+ T cell counts and the CD4+/CD8+ ratio.The plasma levels of fasting glucose, glycosylated haemoglobin (HbA1c), lipid profile, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, C reactive protein (CRP) and D-dimer to assess the hepatic and renal functions.The plasma levels of the following soluble inflammatory factors: interferon-alpha (IFN-α), TNF-α, IL-1, IL-6, IFN-γ-inducible protein 10 (IP-10) and LPS to assess the anti-inflammatory effect of metformin.The composition of the gut microbiota in stool samples.

Methods and analysis {#s2}
====================

Study design, settings, sample size and recruitment strategy {#s2a}
------------------------------------------------------------

The study protocol described herein meets the 2013 Standard Protocol Items: Recommendations for Interventional Trials guidelines.[@R48]

Comparisons will be made by repeated measures of the outcomes at baseline, during and after metformin use ([figure 1](#F1){ref-type="fig"} and in [table 1](#T1){ref-type="table"}).

###### 

Schedule of events

  Visit no                                                  Study visits                   
  --------------------------------------------------------- -------------- --- --- --- --- ---
  Consent form                                              X              X               
  Medical history                                           X                              
  Concomitant medication                                    X              X   X   X   X   
  Eligibility criteria                                      X              X               
  Physical examination                                      X              X       X   X   
  Adverse events                                                           X   X   X   X   X
  Haematology[\*](#tblfn1){ref-type="fn"}                   X              X       X   X   
  Chemistry[†](#tblfn2){ref-type="fn"}                      X              X       X   X   
  T-cell activation and inflammatory markers                               X           X   X
  HIV viral load                                            X              X       X   X   X
  Size of HIV reservoir in latently infected CD4+ T cells                  X           X   X
  Urine pregnancy test                                      X              X               
  Metformin administration                                                     X   X   X   
  Colon mucosal biopsies‡                                                  X           X   
  Stool sample collection for microbiota analysis                          X           X   X

\*Complete blood count, CD4+ and CD8+ T cell counts.

†AST, ALT, Alk Phos, total bilirubin, triglycerides, cholesterol, HDL, LDL, creatinine, blood glucose, lipase, amylase, urea, creatine kinase, serum phosphate and fasting glucose.

‡Optional procedure.

AST, aspartate aminotransferase; ALT, alanine aminotransferase; Alk Phos, alkaline phosphatase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

![Study design depicting study visits, intervention and laboratory assessments. ART, antiretroviral therapy; HbA1c, glycosylated haemoglobin; VL, viral load.](bmjopen-2018-028444f01){#F1}

A total of 22 HIV-infected participants will be recruited; it is estimated that there will be a 10% lost to follow-up/study non-completion. Based on our prior studies, it is expected that approximately 50% of participants will consent to participate in the optional substudy examining the effect of metformin on the composition of the gut immune environment in gut mucosa samples obtained by colonoscopy.[@R50] A convenient sample of 22 participants was chosen without formal power calculations. The data that will be obtained in this study should suffice for calculations for future studies.

Participants will be recruited by clinicians at the Chronic Viral Illness Service at the McGill University Health Centre (Montréal, QC, Canada) and the Immunodeficiency Clinic of the Ottawa Hospital (Ottawa, ON, Canada); each of these clinics provides care to 1300--2300 PLWH. Teleconferences and face-to-face meetings will be organised between the investigators and research nurses to help support patient recruitment. Furthermore, conferences on the importance of inflammation in HIV infection and on innovative therapies to alleviate inflammation (such as metformin) will be organised by the investigators to target community groups, treating physicians and healthcare providers.

Inclusion criteria {#s2b}
------------------

Eligible participants will meet the following criteria to be considered eligible for entry into the study: (1) HIV-1-infected male or female at least 18 years of age; (2) successfully treated with ART for at least 3 years, the time necessary to establish a stable reservoir; (3) individuals on a stable ART regimen with plasma viral load below the limit of detection without any recorded blips for at least 3 months, (4) people with a CD4+/CD8+ ratio ≤0.7 at baseline to select participants with high risk of inflammation and non-AIDS events[@R52] and (5) non-diabetic as defined HbA1c \<5.9% or prediabetic individuals with HbA1c between 6.0% and ≥6.4%.

Exclusion criteria {#s2c}
------------------

Individuals who meet any of the following criteria will be excluded from the study: (1) a known hypersensitivity/allergy to the metformin; (2) active participation in an experimental therapy study or having received experimental therapy within the last 6 months; (3) severe systemic diseases (uncontrolled hypertension, chronic renal failure) or active uncontrolled infections; (4) diabetes mellitus (HbA1c ≥6.5%) as defined by the Canadian Clinical Practice Guidelines for the Prevention and Management of Diabetes[@R24]; (5) oral hypoglycaemic treatment or insulin; (6) statins or other anticholesterol treatments started in the last 3 months since statins are known to be anti inflammatory[@R54]; (7) a history of sickle cell anaemia and/or thalassaemia, impacting HbA1c measurement; (8) a history of congestive heart failure New York Heart Association Classification I-IV or having a cardiac pacemaker; (9) a history of lactic acidosis; (10) current use of stavudine and/or didanosine as metformin can increase the risk of lactic acidosis[@R55]; (11) severe liver or kidney disease based on physician evaluation; (12) elevated aspartate aminotransferase and alanine aminotransferase threefold above the upper normal limit; (13) elevated alkaline phosphatase twofold above upper normal limit; (14) elevated creatinine (above 150 µmol/L); (15) current use of oral steroids; (16) a systemic infection within the last 1 month; (17) women who are pregnant or breast feeding.

Study intervention {#s2d}
------------------

This study will involve 500 mg and 850 mg doses of metformin hydrochloride (Glucophage; Sanofi-Aventis Canada). Metformin will be taken with meals throughout the study duration; in the first week, orally two times daily as 500 mg tablets to assess tolerability, following which the dose will be increased to 850 mg tablets two times daily (weeks 2--12). These doses were chosen based on the mean dose used in diabetic individuals in whom metabolic improvement has been described[@R56]; Treatment duration is based on the duration of use in non-diabetic patients treated for polycystic ovary syndrome in whom an inflammatory effect was observed[@R45]; Compliance will be monitored by the research study nurse at each visit by assessing pill counts and by telephone calls between each visit.

Since concomitant use of dolutegravir and metformin increases the plasma concentration of metformin[@R60]; participants using dolutegravir will take the 500 mg dose metformin two times daily throughout the study. Although the coadministration of dolutegravir and metformin was found to be well tolerated in individuals taking both medications,[@R60] dose reduction of metformin may be considered according to participant tolerance and to clinician judgement.

Use of medications, alcohol, street drugs and natural remedies will be recorded. There will not be any restrictions on the use of natural remedies since none have been found to interact with metformin.

### Adverse events and toxicity management {#s2d1}

During each follow-up visit with a participant, information on adverse events (AEs) will be gathered and documented accordingly. AEs will be graded as mild, moderate, severe or life threatening according to the toxicity table and toxicity guidelines provided by the National Institutes of Health Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, and will be assessed by causality as probably related, possibly related, unlikely to be related or not related to the study drug. The assessment of safety will include clinical observation and monitoring of patient management and changes over times. The Canadian HIV Trials Network (CTN) will be responsible for reporting serious AEs to Health Canada.

Clinical and laboratory assessments {#s2e}
-----------------------------------

### Assessment of HIV reservoir size {#s2e1}

The size of the HIV reservoir in peripheral blood and in colon biopsies (optional substudy) will be measured using PCR-based assays (total and integrated HIV DNA). In addition, the size of the inducible reservoir in blood CD4+ T cells will be measured by TILDA.

Frequency of cells harbouring total and integrated HIV DNA will be measured using a nested quantitative PCR that can detect a single copy of the viral genome in 10^5^ cells.[@R62] While integrated HIV DNA is present in both latently and productively infected cells, the ratio between total and integrated has been shown to reflect residual HIV expression and de novo reverse transcription.[@R63]

As the majority of HIV DNA molecules are not replication competent,[@R64] we will measure the frequency of cells producing HIV multiply spliced (ms) RNAs after T cell receptor (TCR) stimulation in blood CD4+ T-cells using TILDA.[@R47] The estimate of the size of the reservoir provided by TILDA is intermediate between PCR-based assays and quantitative viral outgrowth assays and requires fewer cells. While unspliced HIV RNAs are frequently detected in latently infected cells in the absence of viral production, HIV msRNA (Tat/Rev) reflect active viral production. We will take advantage of this unique feature of msRNA in a limiting dilution assay to measure the frequency of cells with inducible HIV on maximal stimulation in CD4+ T-cells isolated from blood. Briefly, isolated CD4+ T-cells will be stimulated for 12 hours with phorbol myristate acetate/ionomycin. The stimulated cells will be serially diluted in a 96 well plate, lysed and the lysates will be used immediately for reverse transcriptase PCR. msRNA will be quantified by real-time PCR, and by using the maximum likelihood method, the frequency of cells harbouring inducible HIV msRNA in CD4+ T-cells will be calculated. The difference in the relative frequencies of CD4+ T-cells that are either activated or not activated represents the inducible latently infected cells.

### Assessment of T-cell activation in blood {#s2e2}

The levels of T-cell activation will be assessed in blood samples drawn at weeks 0, 12 and 24, as specified in [figure 1](#F1){ref-type="fig"} and [table 1](#T1){ref-type="table"}. Briefly, peripheral blood mononuclear cells (PBMCs) will be obtained by Ficoll gradient centrifugation. The PBMCs will either be labelled with the appropriate monoclonal antibodies or will be stored in liquid nitrogen until analysed. T-cell analysis will be performed using specific monoclonal antibodies as previously reported.[@R41] The associated expressions of CD45RA, CCR7 and CD27 will be used to determine the percentages of naive (CD45RA^+^CCR7^+^CD27^+^), central memory (CD45RA^--^CCR7^+^CD27^+^), preterminal effector memory (CD45RA^--^CCR7^--^CD27^--^), transitional memory (CD45RA^-^CCR7^+^CD27^+^) and terminally differentiated (CD45RA^+^CCR7^--^CD27^--^) CD4+ and CD8+ T-cell subsets. The expression of the activation markers HLA-DR and CD38 will be assessed on the CD4+ and CD8+ T-cell subsets. FlowJo software will be used to analyse the data.

### Assessment of HIV reservoirs and T-cell activation in gut mucosa samples {#s2e3}

Since recent studies suggest that the mucosal immune system is the most important site of T-cell activation in HIV infection,[@R68] the frequency of HLA-DR+CD38+ activated CD8+ T-cells in optional colon mucosal biopsies samples will be determined. Colon biopsies (around 30) will be obtained by colonoscopy performed before metformin administration (week 0) and at the end of metformin treatment (week 12), as specified in [figure 1](#F1){ref-type="fig"} and [table 1](#T1){ref-type="table"}.

Gut T-cells will be isolated from biopsy samples by enzyme digestion using a collagenase-based method as reported previously.[@R68] Briefly, fresh tissue biopsies will be incubated with type II collagenase for 30 min at 37°C in a shaking incubator. Tissues pieces will be mechanically separated by repeated passage through a syringe. Viable lymphocytes will be separated from debris using Ficoll-Hypaque density gradient centrifugation. HIV reservoir will be measured by PCR-based assays (total and integrated HIV DNA) in sorted CD4+ T cells. It is unlikely that TILDA will be performed in mucosal T-cells are their number should be too low. The total frequency of activated CD4+ and CD8+ T-cells will be determined by flow cytometry as described above.

### Assessment of inflammatory cytokines in plasma {#s2e4}

Levels of inflammatory markers such as D-dimer and CRP are related to cardiovascular non-AIDS events during HIV infection. The ability of metformin therapy to reduce plasma levels of IFN-α, IL-1, IL-6, IP-10, TNF-α and LPS will be assessed by ELISA as previously reported.[@R41]

### Assessment of gut microbiota composition {#s2e5}

Recent studies have shown that metformin can change the composition of the gut microbiota.[@R35] We hypothesised that changes in microbiota composition influence markers of inflammation and immune activation. To assess this, stool samples will be collected before (week 0) and after (week 12) metformin therapy, and after 12 weeks of metformin discontinuation (week 24) into clean collection tubes. Stool samples will be immediately stored at −80°C until analysed. DNA will be extracted using the Qiagen Stool Mini Kit. The composition of the gut microbiota will be determined using DNA sequencing of 16S ribosomal RNA region of bacterial taxa.

Statistical analysis {#s2f}
--------------------

Comparisons of HIV reservoir size and percentage of activated T-cells will be made between baseline, week 12 and week 24. The data will be analysed by non-parametric statistical tests such as the Wilcoxon matched pairs test and the Friedman test. The threshold of significance will be 5%.

The same tests will be used to analyse data from blood and colon biopsies. Comparisons will also be made between mucosal and blood compartments within the same participant using the Wilcoxon matched pairs test and the Friedman test.

The Wilcoxon matched pairs test will be used to compare the number of bacterial taxa by type in stool samples before and after metformin therapy.

Patient and public involvement {#s2g}
------------------------------

-   Patients or public were not involved in the design of this study.

-   Compliance questionnaires will allow for assessment of participants' experience.

-   Final results of the study are expected to be published but will not be specifically disseminated to participants.

Ethics and dissemination plan {#s3}
=============================

Written informed consent will be obtained from all participants. All protocol amendments will be submitted to the research ethics board of each participating centre. The Investigator will seek prior ethics approval for any protocol deviations except when the change is intended to eliminate an immediate hazard to participants. In this case, the protocol deviation will be promptly reported to the data safety and monitoring committee of the CTN.

Dissemination plan {#s3a}
------------------

The results of the trial, regardless of outcome, will be disseminated through the traditional routes of scientific peer-reviewed publications, through international and national specialist conferences, and through the press release by CTN.

Discussion {#s4}
==========

The size of the HIV reservoir is influenced by a number of factors including late ART initiation, low CD4+ T-cell count, low CD4+/CD8+ ratio and high level of immune activation.[@R7] Therapies that target and reduce immune activation are therefore critical to reduce the size of the HIV reservoir.

It has been shown that in HIV-specific CD8+ T-cells cellular metabolism is linked to immune responses and acts upstream of immune activation.[@R13] We further propose that immunometabolism, which has been shown to affect the ability of T-cells to proliferate, would regulate optimal cytotoxic responses and influence the size of the HIV reservoir.[@R23] Given metformin's immunomodulatory properties,[@R28] and its ability to improve CD4+ T-cell counts in one study of participants initiating ART,[@R31] we propose that this antidiabetic medication may enhance T-cell effector function to control the HIV reservoir.

This study will test the hypothesis that the coadministration of metformin and ART will decrease the size of the viral reservoir and the levels of immune activation. If so, after 12 weeks of metformin therapy, participants should manifest a decrease in T-cell activation (ie, from week 0 to week 12) that may reverse after metformin discontinuation (ie, from week 12 to week 24) as metformin's anti-inflammatory effects are lost.

We have previously reported a 10-fold difference in the frequency of HLA-DR+CD38+ activated CD8+ T-cells between uninfected controls and aviraemic ART-treated individuals.[@R65] A 50% reduction in the number of activated CD8^+^CD38^+^HLA-DR^+^ T-cells is estimated following metformin treatment. It is expected that the reduction of the frequency of activated CD8+ T-cells by metformin therapy will be more significant in the gut mucosa than in peripheral blood since this mucosal site is the major source of microbial translocation, a process that results in T-cell activation via activation of toll-like receptors.

Furthermore, measurements of circulating cytokines, of inflammatory mediators, and of LPS will be made to determine whether metformin treatment can also reduce or suppress inflammatory mediators known to drive immune activation.

This single-arm pilot study will include 22 participants. Should the results of this study suggest that metformin can reduce immune activation and/or the size of the viral reservoir in HIV-infected participants on suppressive ART, formal sample size calculations can be done for larger future studies.
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